10-Q: Caring Brands Reports Q3 Loss, Going Concern Doubt

Caring Brands, Inc. reported a significant net loss for Q3 2025, with auditors raising substantial doubt about its ability to continue as a going concern.

Summary

• Caring Brands, Inc. reported a net loss of $1,018,768 for the three months ended September 30, 2025, and $2,218,121 for the nine months ended September 30, 2025.
• Net sales for the nine months ended September 30, 2025, were inconsequential at $3,795, with no revenue reported for the comparable 2024 periods.
• Selling, general and administrative (SG&A) expenses significantly increased to $2,200,504 for the nine months ended September 30, 2025, up from $1,083,479 in the combined 2024 period, primarily due to consulting and investor relations services related to a potential NASDAQ uplisting.
• Cash and cash equivalents decreased substantially to $16,123 as of September 30, 2025, from $468,998 at December 31, 2024.
• The company's auditors, M&K CPAS, PLLC, have raised doubt about its ability to continue as a going concern.
• A material weakness in internal controls over financial reporting was identified, as accounting transactions were not initially recorded during financial statement preparation.
• Total debt, net of issuance costs, stood at $131,268 as of September 30, 2025, including a $120,000 term loan and $75,000 in related party notes payable.
• The company has a product pipeline including hair loss treatments, Eczema and Psoriasis Treatments, vitiligo solutions, and a Jellyfish sting protective suncare line, but products are still in development and commercialization.
• Caring Brands expects to raise approximately $4.0 million through a public offering of shares to fund operations for the next twelve months and invest in product development.

Sentiment

Score: 1

Explanation: The company is in a highly precarious financial position, marked by significant losses, critically low cash, a 'going concern' warning from auditors, and identified material weaknesses in internal controls. While a capital raise is planned, its success and sufficiency are uncertain, making the overall outlook extremely negative.

Positives

• The company recently became listed on NASDAQ, which could facilitate future capital raising.
• A public offering of shares is in process, expected to raise approximately $4.0 million, which management believes will provide liquidity for the next twelve months and support product development.
• The company has a diverse product pipeline in health and wellness, including hair loss, eczema, psoriasis, vitiligo, and suncare products.
• Secured a license agreement with NovoDX Corporation for the GoldNTM Ebola Rapid Diagnostic Test, expanding its intellectual property.

Negatives

• Reported a significant net loss of $2,218,121 for the nine months ended September 30, 2025, a substantial increase from the prior year.
• Cash and cash equivalents are critically low at $16,123 as of September 30, 2025, down from $468,998 at December 31, 2024.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Identified a material weakness in internal controls over financial reporting, indicating deficiencies in financial record-keeping.
• Net sales remain inconsequential at $3,795 for the nine months ended September 30, 2025, reflecting the early stage of product commercialization.
• Selling, general and administrative expenses increased significantly, contributing to the overall net loss.
• Total current assets decreased significantly while total current liabilities increased, worsening the company's liquidity position.
• The company is heavily reliant on future capital raises, which may not be available on favorable terms or at all.

Risks

• The company may be unable to achieve some or all of the benefits expected from the separation from Safety Shot, Inc.
• Limited operating history as a publicly traded company makes historical financial information unreliable for future results prediction.
• Potential conflicts of interest exist due to some directors and executive officers owning Safety Shot common stock or holding positions with Safety Shot.
• The company's limited operating history makes it difficult to accurately evaluate business prospects.
• There is a risk of not having adequate capital to fund business operations.
• The company may not be able to successfully compete against companies with substantially greater resources.
• The sale of products involves product liability and related risks that could lead to significant insurance and loss expenses.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or other assets.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Inability to adequately protect intellectual property could hinder effective competition and profitability.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• The common stock may become subject to the SEC's penny stock rules, adversely affecting trading activity.
• A material weakness in internal controls over financial reporting has been identified, which could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company's current cash balance of $16,123 is insufficient to support its plans and initiatives. Management anticipates raising approximately $4.0 million through a public offering of shares, which is expected to provide liquidity for the next twelve months and enable investment in product growth and development. However, additional funds may be necessary for long-term liquidity, potentially through further indebtedness or equity financings, which may not be available on favorable terms or at all.

Management Comments

• The company is still in the process of developing and commercializing its products.
• The increase in professional and investor relations services was primarily a result of the potential uplisting from the OTC market to NASDAQ.
• The current amount of cash will not support the company's plans and initiatives.
• The company is in the process of completing a public offering of shares, from which approximately $4.0 million is expected to be raised.
• These funds will provide enough liquidity through the next twelve months and allow the company to invest in growing and developing its products.
• Disclosure controls and procedures were not yet fully effective as of September 30, 2025, as the company is newly public and in the process of designing and implementing them.
• A material weakness in internal controls over financial reporting was identified, as accounting transactions were not initially recorded during financial statement preparation.

Industry Context

Caring Brands operates in the competitive health and wellness consumer products industry, which includes both over-the-counter and prescription-grade segments. The company's focus on developing and commercializing new products, such as specialized treatments and diagnostic tests, places it in a high-risk, high-reward sector. Its current lack of meaningful revenue and significant cash burn are typical for early-stage biotech or pharmaceutical companies, but the 'going concern' warning and internal control weaknesses highlight severe operational challenges compared to more established industry players. The potential NASDAQ uplisting suggests an ambition to attract broader institutional investment, a common strategy for growth-stage companies seeking to scale.

Comparison to Industry Standards

• The company's minimal revenue ($3,795 for nine months) and substantial net loss ($2.2 million for nine months) are significantly below industry averages for commercial-stage health and wellness companies, indicating it is still in a pre-commercial or very early commercial phase.
• The cash balance of $16,123 is extremely low, far below the working capital typically maintained by even small public companies in the health and wellness sector, which often require substantial capital for R&D, marketing, and regulatory compliance.
• The 'going concern' warning from auditors is a critical red flag, indicating a severe liquidity crisis and a high risk of business failure, which is not standard for a healthy public company.
• The identified material weakness in internal controls over financial reporting is a significant governance issue, suggesting a lack of robust financial infrastructure, which is a deviation from expected public company standards and could deter investors.
• The reliance on related party loans for working capital, such as the $50,000 from the CEO and $25,000 from the Chairman, is common for very early-stage ventures but is not a sustainable or desirable long-term financing strategy for a NASDAQ-listed entity.
• While the company has intellectual property and an investment in NovoDX, the lack of substantial progress in commercializing its diverse product pipeline (hair loss, eczema, Ebola test) suggests slower development or market penetration compared to more successful industry peers like Johnson & Johnson (JNJ) or Pfizer (PFE) in their early product development stages, which typically have more robust funding and R&D pipelines.

Corporate Governance

Legal Proceedings

• The company is not currently aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position.

Related Party Transactions

• Intellectual property, net, a related party, valued at $2,625,000 as of September 30, 2025.
• Investment in NovoDX Corporation, a related party, valued at $500,000 as of September 30, 2025.
• Related party loan payable of $129,405 as of September 30, 2025.
• License Agreement with NovoDX Corporation (a related party) for the GoldNTM Ebola Rapid Diagnostic Test, in exchange for 3,000,000 shares of restricted common stock.
• Short-term loan agreement with CEO, Dr. Glynn Wilson, for $50,000, due November 5, 2025, with an 8% interest rate.
• Short-term loan agreement with Chairman of the Board, Mr. Brian John, for $25,000, due December 24, 2025, with an 8% interest rate.
• Loan with Safety Shot, Inc. (a related party and significant shareholder) for $54,405, representing operating expenses paid on behalf of the company, non-interest bearing, unsecured, with no stated repayment terms.
• Separation and exchange agreement with Safety Shot, Inc. (a related party) on September 24, 2024, where the company assumed all future obligations of the Predecessor.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from the planned public offering and potential future capital raises. The 'going concern' warning and material weakness in internal controls pose substantial risks to investment value.
• **Employees:** The company's precarious financial position and reliance on future capital raises could impact job security and operational stability.
• **Creditors:** Related party loans and other debt carry risk given the company's limited cash and going concern doubt, though some related party loans are unsecured with no stated repayment terms.
• **Customers:** The early stage of product commercialization and financial instability could affect product availability, support, and future innovation.

Next Steps

• Complete the public offering of shares to raise approximately $4.0 million.
• Invest the raised funds into growing and developing products.
• Continue designing and implementing formal processes and controls to address the material weakness in internal controls over financial reporting.
• Seek additional indebtedness or equity financings if long-term liquidity needs are not met by the current capital raise.

Key Dates

Recommendation

Caring Brands, Inc. presents an extremely high-risk investment profile. The company reported a substantial net loss, critically low cash reserves, and received a 'going concern' warning from its auditors. Furthermore, a material weakness in internal controls over financial reporting indicates fundamental operational deficiencies. While a capital raise is planned, its success and the company's ability to achieve profitability remain highly uncertain. The current financial state and governance issues suggest a significant risk of further share price decline and potential business failure, making it an unsuitable investment for all but the most speculative investors.

Keywords

Health and Wellness, OTC products, Prescription-grade products, Ebola diagnostic test, Hair loss treatments, Eczema treatments, Psoriasis treatments, Vitiligo solutions, Suncare, Biotechnology, Pharmaceuticals, Medical diagnostics, SEC filing, 10-Q, CABR, Going concern, Capital raise, Internal controls